Navigation Links
Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
Date:11/12/2007

http://www.lexpharma.com" target="_new">http://www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX2931 and the potential therapeutic and commercial potential of LX2931. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX2931 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
5. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
10. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
11. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... NEW YORK , May 22, 2015 /PRNewswire/ ... segment of the $13 billion global cardiac rhythm ... Kalorama Information.  Kalorama found that Medtronic, St. Jude ... Medical) command 80% of this market segment. The ... Management Device Markets , uses 2015 as a ...
(Date:5/22/2015)... , May 22, 2015 The ... in 2014 and is estimated to reach $90.7 million by ... Browse through the TOC of North America Dental ... with the help of various tables and figures. ... 10% customization on this report.   Dental ...
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage ... regeneration, today announced that J.J. Finkelstein , chief ... corporate overview at two upcoming investor conferences. ... th Annual Microcap Conference on Thursday May 28, ... at 11:00 am EDT.  A webcast will be available ...
Breaking Medicine Technology:Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3
... July 12, 2011 Magellan Biosciences, a global ... easier, more cost-effective, and less labor intensive, announced ... Systems-brand Sensititre AIM Automated Inoculation Delivery System for ... Sensititre AIM System quickly and accurately doses microtitre ...
... Particle Sciences Inc. (PSI), a ... provider of pre-clinical pharmacokinetic services, announced today that ... their clients with enhanced drug development services by ... development scheme.   According to Robert ...
Cached Medicine Technology:New FDA-Cleared Sensititre® AIM™ Automated Inoculation Delivery System Provides Faster, Accurate Dosing of MIC Plates for Microbiology Laboratories 2New FDA-Cleared Sensititre® AIM™ Automated Inoculation Delivery System Provides Faster, Accurate Dosing of MIC Plates for Microbiology Laboratories 3Particle Sciences and Absorption Systems Form Relationship to Offer their Clients Enhanced Services 2
(Date:5/22/2015)... 22, 2015 ZH Healthcare ... solutions, announced today that Bill Lane, joins ZH’s ... developer of BlueEHS,a first of its kind, Freemium ... customizable Electronic Health Records (EHR) with an integrated ... telemedicine-enabled comprehensive patient portal, and more. Combined with ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Gateway Building ... exterior renovations. The services the company specialize in include ... remodeling, basements, pool houses and much more. , ... by the owner of the company. It includes two ... The design was thought out to be used with ...
(Date:5/22/2015)... A Phase 3 French study, which ... Clinical Oncology (ASCO)’s annual meeting at the end ... patients who received bevacizumab in addition to the ... Genentech, Inc.) is an antibody that blocks angiogenesis ... used to treat many other cancers, including lung ...
(Date:5/22/2015)... 22, 2015 Ticket Down is a reputable ... Rangers NHL Eastern Conference Finals Tickets . All seating ... otherwise in the ticket listing. , For the first ... the top of the Eastern Conference. One of the original ... of ups and downs over the years, but the excitement ...
(Date:5/22/2015)... In April 2006, Veatch Consulting opened ... years they have concentrated their focus to working with ... Because of this growth and their goals to better ... Denver, Colorado, Cleveland, Ohio, Houston, Texas and now Dallas, ... dental offices, dental start ups, orthodontic practices, pediatric dental ...
Breaking Medicine News(10 mins):Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 3
... (Nasdaq: DATA ), a technology and services company ... today reported its,operating results for the fourth quarter and ... ended December 31, 2007, revenue decreased,approximately 54% to $1,839,000 ... $(0.18) per share on both a basic and diluted ...
... 26 Bad reactions to a,prescribed medication send more ... Just 10 commonly used medications -- almost all,of them ... of these,reactions. The March 2008 issue of the Harvard ... potentially tricky medications., Warfarin: Check your bleeding time ...
... lead clinical efforts of Pennsylvania-based contracts, HARRISBURG, ... rapidly,expanding national medical management firm, named Stuart B. ... who replaces retiring medical,director, Frank Castrina, MD, will ... KePRO,s Harrisburg headquarters., "Dr. Chesky,s combined medical ...
... Unique, crystalline laxative designed to enhance patient acceptance and ... ... 26 Kristalose(R), a prescription,laxative product that treats acute and chronic ... a prescription,alternative to MiraLAX(R) and generic PEG 3350 products. Marketed in ...
... Plexus Systems, Inc.,provider of Plexus Online on-demand software ... Senior Account Manager of the,Western United States. He ... needs are met., (Logo: http://www.newscom.com/cgi-bin/prnh/20070627/CLW071LOGO ... record of selling and delivering large,Enterprise Resource Planning ...
... Physician Practices in Florida and Texas, ... Availity,L.L.C. and Prematics(TM) today announced an ... electronic prescribing service under,Availity,s private label, CarePrescribe(SM). ... physician support on behalf of Availity and,its ...
Cached Medicine News:Health News:DATATRAK International Reports Fourth Quarter and Full Year Results for 2007 2Health News:DATATRAK International Reports Fourth Quarter and Full Year Results for 2007 3Health News:DATATRAK International Reports Fourth Quarter and Full Year Results for 2007 4Health News:DATATRAK International Reports Fourth Quarter and Full Year Results for 2007 5Health News:DATATRAK International Reports Fourth Quarter and Full Year Results for 2007 6Health News:DATATRAK International Reports Fourth Quarter and Full Year Results for 2007 7Health News:DATATRAK International Reports Fourth Quarter and Full Year Results for 2007 8Health News:Tips for Troublesome Medications, From the Harvard Heart Letter 2Health News:KePRO Names Stuart B. Chesky, DO, JD, as Pennsylvania Medical Director 2Health News:KePRO Names Stuart B. Chesky, DO, JD, as Pennsylvania Medical Director 3Health News:Kristalose(R) Offers Prescription Alternative to MiraLAX(R) and Other PEG 3350 Products 2Health News:Kristalose(R) Offers Prescription Alternative to MiraLAX(R) and Other PEG 3350 Products 3Health News:Plexus Systems, Inc. Names Khanna to Senior Account Manager - Western Region 2Health News:Availity Engages Prematics to Deploy Electronic Prescribing 2Health News:Availity Engages Prematics to Deploy Electronic Prescribing 3
... Ultra High Throughput Screening (UHTS), Analyst ... performance. Allows for smooth transfer of ... by sharing all the detection modalities ... intensity, fluorescence polarization, time-resolved fluorescence, luminescence, ...
... POLARstar OPTIMA is a fully automated ... five different measurement principles:, , Fluorescence ... Time-Resolved Fluorescence , High-Performance Luminescence ... ,It is designed for ...
... assays, in 6 to 1536 well formats, ... is the instrument that can meet all ... the AlphaScreen assay platform. There are ... Reads AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) ...
VICTOR2 V measures prompt fluorescence, fluorescence polarization, luminescence, time-resolved fluorescence and absorbance. This model includes high density TRF (for 1536-well plates), temperature ...
Medicine Products: